HealthLinx Confirms Collaborators for Ovarian Cancer Diagnostic Study

HealthLinx has confirmed its collaborators who will work with the company on its second larger OvPlex ovarian cancer diagnostic trial. The trial using 1150 samples will take place in Australia, Singapore and the UK and include:

· Professor Lewis Perrin, director of Gynaecological Oncology at Mater Hospital, Brisbane, Australia

· Mahesh Choolani, associate professor of Obstetrics and Gynaecology at Yong Loo Lin School of Medicine, National University of Singapore

· Khalil Razvi, clinical director, Obstetrician and Gynaecology at Southend Hospital, Essex, UK

· Dr John Green, School of Cancer Studies at University of Liverpool and National Cancer Research Institute Clinical Studies Group, UK

The company has engaged researchers and clinicians in the field of ovarian cancer. The collaborators will contribute patient plasma samples, knowledge and clinical expertise that will enhance the development path for OvPlex. This is the company’s second and larger biomarker trial.

“The trial will commence first quarter 2010 and will further evaluate the performance of the current OvPlex panel and establish the clinical utility of HTX005 and HTX010. On the basis of studies completed to date, we believe these new markers will increase the diagnostic performance of the panel to greater than 97 percent. A high level of interest will focus on the performance of the novel biomarker HTX005. This is considered by HealthLinx scientists and its collaborators to be one of the team’s most interesting biomarkers with huge potential,” said Nick Gatsios, MD of HealthLinx.

A successful outcome will mean that the company can progress with registration of the panel in multiple jurisdictions and seek to partner the technology for global roll out.

The study involves up to 1150 patient samples and focuses on the detection of early stage symptomatic women. If successful, the company will have a first in class ovarian cancer diagnostic for early stage detection.